Circulating Tumor Cells (CTCs) Prognostic Technologies Market, Global Outlook and Forecast 2022-2028

March 2022 | 63 pages | ID: C4B8691C25B6EN
Market Monitor Global

Abstracts

Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.

This report contains market size and forecasts of Circulating Tumor Cells (CTCs) Prognostic Technologies in Global, including the following market information:

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Circulating Tumor Cells (CTCs) Prognostic Technologies market was valued at 1493.8 million in 2021 and is projected to reach US$ 3797.9 million by 2028, at a CAGR of 14.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Tumor Cell Enrichment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Circulating Tumor Cells (CTCs) Prognostic Technologies include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Circulating Tumor Cells (CTCs) Prognostic Technologies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Segment Percentages, by Type, 2021 (%)

• Tumor Cell Enrichment
• Tumor Cell Detection

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Segment Percentages, by Application, 2021 (%)

• Prostate Cancer
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Circulating Tumor Cells (CTCs) Prognostic Technologies revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Circulating Tumor Cells (CTCs) Prognostic Technologies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AdnaGen
• ACDBio
• Celula
• Epic Sciences
• Fluxion Biosciences
• Rarecells
• Silicon Biosystems
• Vitatex

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CIRCULATING TUMOR CELLS (CTCS) PROGNOSTIC TECHNOLOGIES OVERALL MARKET SIZE

2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size: 2021 VS 2028
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players in Global Market
3.2 Top Global Circulating Tumor Cells (CTCs) Prognostic Technologies Companies Ranked by Revenue
3.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor Cells (CTCs) Prognostic Technologies Companies in Global Market, by Revenue in 2021
3.5 Global Companies Circulating Tumor Cells (CTCs) Prognostic Technologies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor Cells (CTCs) Prognostic Technologies Players in Global Market
  3.6.1 List of Global Tier 1 Circulating Tumor Cells (CTCs) Prognostic Technologies Companies
  3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor Cells (CTCs) Prognostic Technologies Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Markets, 2021 & 2028
  4.1.2 Tumor Cell Enrichment
  4.1.3 Tumor Cell Detection
4.2 By Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue & Forecasts
  4.2.1 By Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2022
  4.2.2 By Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2023-2028
  4.2.3 By Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2021 & 2028
  5.1.2 Prostate Cancer
  5.1.3 Breast Cancer
  5.1.4 Colorectal Cancer
  5.1.5 Lung Cancer
  5.1.6 Ovarian Cancer
  5.1.7 Pancreatic Cancer
5.2 By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue & Forecasts
  5.2.1 By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2022
  5.2.2 By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2023-2028
  5.2.3 By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2021 & 2028
6.2 By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue & Forecasts
  6.2.1 By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2022
  6.2.2 By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2023-2028
  6.2.3 By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028
  6.3.2 US Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.3.3 Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.3.4 Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028
  6.4.2 Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.3 France Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.4 U.K. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.5 Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.6 Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.7 Nordic Countries Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.4.8 Benelux Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028
  6.5.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.5.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.5.4 South Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.5.5 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.5.6 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028
  6.6.2 Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.6.3 Argentina Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028
  6.7.2 Turkey Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.7.3 Israel Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.7.4 Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028
  6.7.5 UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AdnaGen
  7.1.1 AdnaGen Corporate Summary
  7.1.2 AdnaGen Business Overview
  7.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.1.4 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.1.5 AdnaGen Key News
7.2 ACDBio
  7.2.1 ACDBio Corporate Summary
  7.2.2 ACDBio Business Overview
  7.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.2.4 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.2.5 ACDBio Key News
7.3 Celula
  7.3.1 Celula Corporate Summary
  7.3.2 Celula Business Overview
  7.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.3.4 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.3.5 Celula Key News
7.4 Epic Sciences
  7.4.1 Epic Sciences Corporate Summary
  7.4.2 Epic Sciences Business Overview
  7.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.4.4 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.4.5 Epic Sciences Key News
7.5 Fluxion Biosciences
  7.5.1 Fluxion Biosciences Corporate Summary
  7.5.2 Fluxion Biosciences Business Overview
  7.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.5.4 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.5.5 Fluxion Biosciences Key News
7.6 Rarecells
  7.6.1 Rarecells Corporate Summary
  7.6.2 Rarecells Business Overview
  7.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.6.4 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.6.5 Rarecells Key News
7.7 Silicon Biosystems
  7.7.1 Silicon Biosystems Corporate Summary
  7.7.2 Silicon Biosystems Business Overview
  7.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.7.4 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.7.5 Silicon Biosystems Key News
7.8 Vitatex
  7.8.1 Vitatex Corporate Summary
  7.8.2 Vitatex Business Overview
  7.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Major Product Offerings
  7.8.4 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global Market (2017-2022)
  7.8.5 Vitatex Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Opportunities & Trends in Global Market
Table 2. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Drivers in Global Market
Table 3. Circulating Tumor Cells (CTCs) Prognostic Technologies Market Restraints in Global Market
Table 4. Key Players of Circulating Tumor Cells (CTCs) Prognostic Technologies in Global Market
Table 5. Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Share by Companies, 2017-2022
Table 8. Global Companies Circulating Tumor Cells (CTCs) Prognostic Technologies Product Type
Table 9. List of Global Tier 1 Circulating Tumor Cells (CTCs) Prognostic Technologies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Circulating Tumor Cells (CTCs) Prognostic Technologies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2023-2028
Table 30. AdnaGen Corporate Summary
Table 31. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 32. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 33. ACDBio Corporate Summary
Table 34. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 35. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 36. Celula Corporate Summary
Table 37. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 38. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 39. Epic Sciences Corporate Summary
Table 40. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 41. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 42. Fluxion Biosciences Corporate Summary
Table 43. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 44. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 45. Rarecells Corporate Summary
Table 46. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 47. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 48. Silicon Biosystems Corporate Summary
Table 49. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 50. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)
Table 51. Vitatex Corporate Summary
Table 52. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Product Offerings
Table 53. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Circulating Tumor Cells (CTCs) Prognostic Technologies Segment by Type in 2021
Figure 2. Circulating Tumor Cells (CTCs) Prognostic Technologies Segment by Application in 2021
Figure 3. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2021
Figure 8. By Type - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 9. By Application - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 10. By Region - Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 11. By Country - North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 12. US Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 16. Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 17. France Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 24. China Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 28. India Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 30. Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share, 2017-2028
Figure 33. Turkey Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue, (US$, Mn), 2017-2028
Figure 37. AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)